중추신경계 치료제 시장 규모, 점유율, 동향 분석 보고서 : 질환별, 약물 종류별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)

Central Nervous System Therapeutics Market Summary

The global central nervous system therapeutics market size was estimated at USD 138.59 billion in 2025 and is projected to reach USD 273.32 billion by 2033, growing at a CAGR of 9.1% from 2026 to 2033. The central nervous system (CNS) therapeutics market is experiencing robust growth, driven largely by the rising prevalence of neurological and psychiatric disorders.

As the global population ages, coupled with the impact of modern lifestyle choices, the incidence of diseases such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and mental health disorders is steadily increasing. This expanding disease burden is catalyzing significant demand for new and improved therapeutic options. As the need for effective treatments grows, pharmaceutical and biotechnology companies are ramping up investments in CNS drug development, and governments are offering increased support for research initiatives.

The global aging population is one of the most significant drivers of rising disease prevalence in the CNS therapeutics market. According to the WHO, the ratio of the world's population aged 60 years and older is anticipated to double by 2050, from approximately 12% in 2015 to 22%. Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and other dementias, are primarily age-related and are becoming more prevalent as life expectancy increases. Alzheimer's disease, which currently affects more than 55 million people worldwide, is predicted to nearly triple by 2050. Similarly, Parkinson's disease affects an estimated 10 million people globally, and this number is expected to rise due to the aging population. As a result, there is a growing demand for effective treatments, particularly those that can delay the progression of these debilitating diseases or modify their course. Despite the increasing prevalence, current treatment options for neurodegenerative diseases remain limited, with no cure available. This has led to increased investment in novel therapies, including disease-modifying treatments and targeted drug delivery systems aimed at overcoming the blood-brain barrier.

Beyond aging, modern lifestyle factors such as stress, poor diet, sedentary behavior, and environmental pollution are contributing to the rising prevalence of both neurological and psychiatric disorders. These factors have been linked to an increase in stroke, migraine, and mental health conditions such as anxiety, depression, schizophrenia, and bipolar disorder. Mental health issues are becoming a leading cause of disability worldwide. The WHO estimates that over 300 million people suffer from depression globally, and the number is steadily increasing. This growing prevalence of psychiatric disorders is pushing for new therapeutic options that address the root causes of conditions such as depression and schizophrenia. The need for treatments that are more effective, have fewer side effects, and offer better long-term outcomes has never been greater.

The rising prevalence of Alzheimer's disease is expected to boost market growth. Alzheimer's disease is a global epidemic, and its diagnosis rate is about 25% globally. The diagnosis rate of Alzheimer's disease is high in developed countries. In North America and some European countries, the diagnosis rate of Alzheimer's disease is nearly 50%, whereas, in developing countries such as India & China, it varies from 10%-15% of total Alzheimer's cases. In addition, according to NCBI, in 2021, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer's disease, which is estimated to increase to around 13.8 million by 2060.

Furthermore, an increase in the incidence and cost burden of dementia associated with Alzheimer's disease worldwide is expected to boost market growth. According to the Alzheimer's Society, there are around 900,000 people living with dementia in the UK, and it is projected to rise to 1.6 million by 2040 and the incidence of dementia will be 209,600 in the same year.

Alzheimer's disease is becoming the most common cause of death in neurodegenerative diseases and a common cause of physical disability. The disease is most common in females as compared to males. For instance, two in three people with the disease are women. The age distribution for Alzheimer's disease across the globe includes 4% aged 65 or younger, 13% aged between 65 and 74, 44% aged 75 to 84, and 38% aged 85 or older.

Global Central Nervous System Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global central nervous system therapeutics market report based on disease, drug class, distribution channel, and region:

• Disease Outlook (Revenue, USD Million, 2021 - 2033)
• Neurovascular Diseases
• CNS Trauma
• Mental Health
  • Anxiety Disorders
  • Epilepsy
  • Mood Disorders
  • Psychotic Disorders
  • Others
• Neurodegenerative Diseases
  • Alzheimer's Disease
  • Parkinsosn's Disease
  • Multiple Sclerosis
  • Huntington's Disease
  • Amytrophic Lateral Sclerosis
  • Others
• Infectious Diseases
• CNS Cancer
• Others
• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
• Antidepressants
• Antipsychotics
• Antiepileptics (AEDs)
• Dopaminergic Agents
• Neuroprotective Agents
• Immunomodulators
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacy
• Retail Pharmacy
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease
  • 1.2.2. Drug Class
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Central Nervous System Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Central Nervous System Therapeutics Market: Disease Business Analysis

• 4.1. Disease Market Share, 2025 & 2033
• 4.2. Disease Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
• 4.4. Neurovascular Diseases
  • 4.4.1. Neurovascular Diseases Market, 2021 - 2033 (USD Million)
• 4.5. CNS Trauma
  • 4.5.1. CNS Trauma Market, 2021 - 2033 (USD Million)
• 4.6. Mental Health
  • 4.6.1. Mental Health Market, 2021 - 2033 (USD Million)
  • 4.6.2. Anxiety Disorders
    • 4.6.2.1. Anxiety Disorders Market, 2021 - 2033 (USD Million)
  • 4.6.3. Epilepsy
    • 4.6.3.1. Epilepsy Market, 2021 - 2033 (USD Million)
  • 4.6.4. Mood Disorders
    • 4.6.4.1. Mood Disorders Market, 2021 - 2033 (USD Million)
  • 4.6.5. Psychotic Disorders
    • 4.6.5.1. Psychotic Disorders Market, 2021 - 2033 (USD Million)
  • 4.6.6. Others
    • 4.6.6.1. Others Market, 2021 - 2033 (USD Million)
• 4.7. Neurodegenerative Diseases
  • 4.7.1. Neurodegenerative Diseases Market, 2021 - 2033 (USD Million)
  • 4.7.2. Alzheimer's Disease
    • 4.7.2.1. Alzheimer's Disease Market, 2021 - 2033 (USD Million)
  • 4.7.3. Parkinsosn's Disease
    • 4.7.3.1. Parkinsosn's Disease Market, 2021 - 2033 (USD Million)
  • 4.7.4. Multiple Sclerosis
    • 4.7.4.1. Multiple Sclerosis Market, 2021 - 2033 (USD Million)
  • 4.7.5. Huntington's Disease
    • 4.7.5.1. Huntington's Disease Market, 2021 - 2033 (USD Million)
  • 4.7.6. Amytrophic Lateral Sclerosis
    • 4.7.6.1. Amytrophic Lateral Sclerosis Market, 2021 - 2033 (USD Million)
  • 4.7.7. Others
    • 4.7.7.1. Others Market, 2021 - 2033 (USD Million)
• 4.8. Infectious Diseases
  • 4.8.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
• 4.9. CNS Cancer
  • 4.9.1. CNS Cancer Market, 2021 - 2033 (USD Million)
• 4.10. Others
  • 4.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Central Nervous System Therapeutics Market: Drug Class Business Analysis

• 5.1. Drug Class Market Share, 2025 & 2033
• 5.2. Drug Class Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug class, 2021 to 2033 (USD Million)
• 5.4. Antidepressants
  • 5.4.1. Antidepressants Market, 2021 - 2033 (USD Million)
• 5.5. Antipsychotics
  • 5.5.1. Antipsychotics Market, 2021 - 2033 (USD Million)
• 5.6. Antiepileptics (AEDs)
  • 5.6.1. Antiepileptics (AEDs) Market, 2021 - 2033 (USD Million)
• 5.7. Dopaminergic Agents
  • 5.7.1. Dopaminergic Agents Market, 2021 - 2033 (USD Million)
• 5.8. Neuroprotective Agents
  • 5.8.1. Neuroprotective Agents Market, 2021 - 2033 (USD Million)
• 5.9. Immunomodulators
  • 5.9.1. Immunomodulators Market, 2021 - 2033 (USD Million)
• 5.10. Others
  • 5.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Central Nervous System Therapeutics Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2025 & 2033
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
• 6.4. Hospital Pharmacy
  • 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
• 6.5. Retail Pharmacy
  • 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Central Nervous System Therapeutics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America Central Nervous System Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Drug Class Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Drug Class Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. U.S. Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Drug Class Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Drug Class Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. Uk Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Drug Class Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Drug Class Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Drug Class Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Drug Class Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Drug Class Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Drug Class Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Drug Class Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Drug Class Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Drug Class Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Drug Class Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Drug Class Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Drug Class Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Drug Class Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Drug Class Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Japan Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Drug Class Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. China Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Drug Class Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Drug Class Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Drug Class Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Drug Class Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Biogen
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Disease Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Otsuka Pharmaceutical Co., Ltd.
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Disease Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Eli Lilly and Company
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Disease Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Merck & Co., Inc.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Disease Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. AstraZeneca
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Disease Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Takeda Pharmaceutical Company Limited.
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Disease Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Novartis AG
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Disease Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Teva Pharmaceutical Industries Ltd.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Disease Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Johnson & Johnson Services, Inc.
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Disease Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Pfizer, Inc.
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Disease Benchmarking
    • 8.5.10.4. Strategic Initiatives